Retatrutide 10 mg is a synthetic triple-agonist peptide under investigation in metabolic research. Designed to engage GIP, GLP-1, and glucagon receptors simultaneously, it has been studied in preclinical models of energy expenditure, glucose handling, and body-composition research.
Research Profile
- Triple-agonist activity across GIP, GLP-1, and glucagon receptors
- Studied in metabolic and energy-balance research models
- Lyophilized format for stable, long-term storage
- QC verified by HPLC and mass spectrometry
Specifications
- Compound: Retatrutide (LY3437943)
- Dosage: 10 mg per vial
- Purity: ≥ 98% (HPLC)
- Form: Lyophilized powder
- Storage: 2–8 °C (lyophilized); –20 °C (reconstituted)
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
